Loss of TARG1 sensitizes cancer cells to inhibitors of topoisomerase II and PARP inhibitors, triggering a synthetic lethality mechanism driven by a toxic accumulation of mADPr that induces replication stress and genomic instability [135]. This evidence concerns the gene PARP1 and cancer.